Medical history relevant to COVID-19 infection
| System organ class, preferred term . | COVID-19 vaccination status . | |
|---|---|---|
| No vaccination (n = 427) . | Vaccinated (n = 372) . | |
| Vascular disorders | 153 (35.8) | 133 (35.8) |
| Hypertension | 141 (33.0) | 128 (34.4) |
| Arteriosclerosis | 7 (1.6) | 4 (1.1) |
| Essential hypertension | 8 (1.9) | 3 (0.8) |
| Aortic arteriosclerosis | 1 (0.2) | 1 (0.3) |
| Metabolism and nutrition disorders | 54 (12.6) | 53 (14.2) |
| Diabetes mellitus | 18 (4.2) | 23 (6.2) |
| Type 2 diabetes mellitus | 20 (4.7) | 15 (4.0) |
| Obesity | 18 (4.2) | 16 (4.3) |
| Overweight | 0 | 2 (0.5) |
| Central obesity | 0 | 1 (0.3) |
| Respiratory, thoracic, and mediastinal disorders | 37 (8.7) | 36 (9.7) |
| Asthma | 11 (2.6) | 17 (4.6) |
| Chronic obstructive pulmonary disease | 10 (2.3) | 5 (1.3) |
| Pulmonary embolism | 2 (0.5) | 10 (2.7) |
| Chronic bronchitis | 5 (1.2) | 3 (0.8) |
| Pulmonary fibrosis | 6 (1.4) | 0 |
| Emphysema | 4 (0.9) | 1 (0.3) |
| Bronchiectasis | 2 (0.5) | 2 (0.5) |
| Idiopathic pulmonary fibrosis | 1 (0.2) | 0 |
| Lung disorder | 0 | 1 (0.3) |
| Cardiac disorders | 29 (6.8) | 24 (6.5) |
| Atrial fibrillation | 12 (2.8) | 9 (2.4) |
| Myocardial ischemia | 3 (0.7) | 5 (1.3) |
| Coronary artery disease | 6 (1.4) | 1 (0.3) |
| Myocardial infarction | 3 (0.7) | 2 (0.5) |
| Aortic valve incompetence | 1 (0.2) | 1 (0.3) |
| Cardiac valve disease | 1 (0.2) | 1 (0.3) |
| Ischemic cardiomyopathy | 1 (0.2) | 1 (0.3) |
| Left ventricular hypertrophy | 1 (0.2) | 1 (0.3) |
| Mitral valve prolapse | 2 (0.5) | 0 |
| Supraventricular extrasystoles | 1 (0.2) | 1 (0.3) |
| Supraventricular tachycardia | 1 (0.2) | 1 (0.3) |
| Atrial flutter | 0 | 1 (0.3) |
| Cardiac failure | 1 (0.2) | 0 |
| Chronic cardiac failure | 1 (0.2) | 0 |
| Congestive cardiac failure | 1 (0.2) | 0 |
| Cardiomegaly | 1 (0.2) | 0 |
| Cardiomyopathy | 0 | 1 (0.3) |
| Coronary artery stenosis | 1 (0.2) | 0 |
| Mitral valve incompetence | 1 (0.2) | 0 |
| Myocardial fibrosis | 1 (0.2) | 0 |
| Myocarditis | 0 | 1 (0.3) |
| Tricuspid valve incompetence | 0 | 1 (0.3) |
| Neoplasms (benign, malignant, and unspecified; including cysts and polyps) | 16 (3.7) | 16 (4.3) |
| Prostate cancer | 4 (0.9) | 6 (1.6) |
| Breast cancer | 5 (1.2) | 3 (0.8) |
| Hodgkin disease | 0 | 2 (0.5) |
| Malignant melanoma | 2 (0.5) | 0 |
| Adenocarcinoma | 0 | 1 (0.3) |
| Bladder transitional cell carcinoma | 0 | 1 (0.3) |
| Cervix carcinoma | 1 (0.2) | 0 |
| Endometrial cancer | 0 | 1 (0.3) |
| Invasive ductal breast carcinoma | 1 (0.2) | 0 |
| Laryngeal squamous cell carcinoma | 1 (0.2) | 0 |
| Papillary thyroid cancer | 0 | 1 (0.3) |
| Thyroid cancer | 0 | 1 (0.3) |
| Thyroid neoplasm | 1 (0.2) | 0 |
| Tonsil cancer | 1 (0.2) | 0 |
| Ureteric cancer | 0 | 1 (0.3) |
| Uterine cancer | 0 | 1 (0.3) |
| Infections and infestations | 14 (3.3) | 12 (3.2) |
| COVID-19 | 6 (1.4) | 6 (1.6) |
| COVID-19 pneumonia | 5 (1.2) | 1 (0.3) |
| Chronic pyelonephritis | 3 (0.7) | 0 |
| Tuberculosis | 0 | 3 (0.8) |
| Pulmonary tuberculosis | 0 | 2 (0.5) |
| Hepatobiliary disorders | 10 (2.3) | 10 (2.7) |
| Hepatic steatosis | 9 (2.1) | 9 (2.4) |
| Liver disorder | 1 (0.2) | 1 (0.3) |
| Renal and urinary disorders | 3 (0.7) | 6 (1.6) |
| Chronic kidney disease | 3 (0.7) | 6 (1.6) |
| Investigations | 0 | 4 (1.1) |
| Body mass index increased | 0 | 3 (0.8) |
| SARS-CoV-2 test positive | 0 | 1 (0.3) |
| Nervous system disorders | 3 (0.7) | 1 (0.3) |
| Carotid artery stenosis | 2 (0.5) | 1 (0.3) |
| Carotid arteriosclerosis | 1 (0.2) | 0 |
| Congenital, familial, and genetic disorders | 1 (0.2) | 1 (0.3) |
| Hypertrophic cardiomyopathy | 1 (0.2) | 0 |
| Noncompaction cardiomyopathy | 0 | 1 (0.3) |
| System organ class, preferred term . | COVID-19 vaccination status . | |
|---|---|---|
| No vaccination (n = 427) . | Vaccinated (n = 372) . | |
| Vascular disorders | 153 (35.8) | 133 (35.8) |
| Hypertension | 141 (33.0) | 128 (34.4) |
| Arteriosclerosis | 7 (1.6) | 4 (1.1) |
| Essential hypertension | 8 (1.9) | 3 (0.8) |
| Aortic arteriosclerosis | 1 (0.2) | 1 (0.3) |
| Metabolism and nutrition disorders | 54 (12.6) | 53 (14.2) |
| Diabetes mellitus | 18 (4.2) | 23 (6.2) |
| Type 2 diabetes mellitus | 20 (4.7) | 15 (4.0) |
| Obesity | 18 (4.2) | 16 (4.3) |
| Overweight | 0 | 2 (0.5) |
| Central obesity | 0 | 1 (0.3) |
| Respiratory, thoracic, and mediastinal disorders | 37 (8.7) | 36 (9.7) |
| Asthma | 11 (2.6) | 17 (4.6) |
| Chronic obstructive pulmonary disease | 10 (2.3) | 5 (1.3) |
| Pulmonary embolism | 2 (0.5) | 10 (2.7) |
| Chronic bronchitis | 5 (1.2) | 3 (0.8) |
| Pulmonary fibrosis | 6 (1.4) | 0 |
| Emphysema | 4 (0.9) | 1 (0.3) |
| Bronchiectasis | 2 (0.5) | 2 (0.5) |
| Idiopathic pulmonary fibrosis | 1 (0.2) | 0 |
| Lung disorder | 0 | 1 (0.3) |
| Cardiac disorders | 29 (6.8) | 24 (6.5) |
| Atrial fibrillation | 12 (2.8) | 9 (2.4) |
| Myocardial ischemia | 3 (0.7) | 5 (1.3) |
| Coronary artery disease | 6 (1.4) | 1 (0.3) |
| Myocardial infarction | 3 (0.7) | 2 (0.5) |
| Aortic valve incompetence | 1 (0.2) | 1 (0.3) |
| Cardiac valve disease | 1 (0.2) | 1 (0.3) |
| Ischemic cardiomyopathy | 1 (0.2) | 1 (0.3) |
| Left ventricular hypertrophy | 1 (0.2) | 1 (0.3) |
| Mitral valve prolapse | 2 (0.5) | 0 |
| Supraventricular extrasystoles | 1 (0.2) | 1 (0.3) |
| Supraventricular tachycardia | 1 (0.2) | 1 (0.3) |
| Atrial flutter | 0 | 1 (0.3) |
| Cardiac failure | 1 (0.2) | 0 |
| Chronic cardiac failure | 1 (0.2) | 0 |
| Congestive cardiac failure | 1 (0.2) | 0 |
| Cardiomegaly | 1 (0.2) | 0 |
| Cardiomyopathy | 0 | 1 (0.3) |
| Coronary artery stenosis | 1 (0.2) | 0 |
| Mitral valve incompetence | 1 (0.2) | 0 |
| Myocardial fibrosis | 1 (0.2) | 0 |
| Myocarditis | 0 | 1 (0.3) |
| Tricuspid valve incompetence | 0 | 1 (0.3) |
| Neoplasms (benign, malignant, and unspecified; including cysts and polyps) | 16 (3.7) | 16 (4.3) |
| Prostate cancer | 4 (0.9) | 6 (1.6) |
| Breast cancer | 5 (1.2) | 3 (0.8) |
| Hodgkin disease | 0 | 2 (0.5) |
| Malignant melanoma | 2 (0.5) | 0 |
| Adenocarcinoma | 0 | 1 (0.3) |
| Bladder transitional cell carcinoma | 0 | 1 (0.3) |
| Cervix carcinoma | 1 (0.2) | 0 |
| Endometrial cancer | 0 | 1 (0.3) |
| Invasive ductal breast carcinoma | 1 (0.2) | 0 |
| Laryngeal squamous cell carcinoma | 1 (0.2) | 0 |
| Papillary thyroid cancer | 0 | 1 (0.3) |
| Thyroid cancer | 0 | 1 (0.3) |
| Thyroid neoplasm | 1 (0.2) | 0 |
| Tonsil cancer | 1 (0.2) | 0 |
| Ureteric cancer | 0 | 1 (0.3) |
| Uterine cancer | 0 | 1 (0.3) |
| Infections and infestations | 14 (3.3) | 12 (3.2) |
| COVID-19 | 6 (1.4) | 6 (1.6) |
| COVID-19 pneumonia | 5 (1.2) | 1 (0.3) |
| Chronic pyelonephritis | 3 (0.7) | 0 |
| Tuberculosis | 0 | 3 (0.8) |
| Pulmonary tuberculosis | 0 | 2 (0.5) |
| Hepatobiliary disorders | 10 (2.3) | 10 (2.7) |
| Hepatic steatosis | 9 (2.1) | 9 (2.4) |
| Liver disorder | 1 (0.2) | 1 (0.3) |
| Renal and urinary disorders | 3 (0.7) | 6 (1.6) |
| Chronic kidney disease | 3 (0.7) | 6 (1.6) |
| Investigations | 0 | 4 (1.1) |
| Body mass index increased | 0 | 3 (0.8) |
| SARS-CoV-2 test positive | 0 | 1 (0.3) |
| Nervous system disorders | 3 (0.7) | 1 (0.3) |
| Carotid artery stenosis | 2 (0.5) | 1 (0.3) |
| Carotid arteriosclerosis | 1 (0.2) | 0 |
| Congenital, familial, and genetic disorders | 1 (0.2) | 1 (0.3) |
| Hypertrophic cardiomyopathy | 1 (0.2) | 0 |
| Noncompaction cardiomyopathy | 0 | 1 (0.3) |
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.